SCHEMBL31270218

SCHEMBL31270218

NC(=O)CCN1CCC2(CCOC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
GLA P06280 1/20 0.39
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
GRM2 Q14416 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HDAC2 Q92769 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 6/20 0.33
KMT2A Q03164 5/20 0.33
ALDH1A1 P00352 5/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.32
HDAC6 Q9UBN7 1/20 0.31
POLB P06746 1/20 0.31
LMNA P02545 2/20 0.31
MPI P34949 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31270210 0.91 L3MBTL1 (0.42) L3MBTL1GLAITGB3ITGA2BGRM2
SCHEMBL31270285 0.90 L3MBTL1 (0.52) L3MBTL1GLAITGB3ITGA2BKDM4E
SCHEMBL31270251 0.88 L3MBTL1 (0.53) L3MBTL1GLAITGB3ITGA2BKDM4E
SCHEMBL31270162 0.82 L3MBTL1 (0.46) L3MBTL1GLAITGB3ITGA2BKDM4E
SCHEMBL31270083 0.78 L3MBTL1 (0.44) L3MBTL1GLAITGB3ITGA2BKDM4E
SCHEMBL31269835 0.78 L3MBTL1 (0.62) L3MBTL1GLAITGB3ITGA2BKDM4E
SCHEMBL31269932 0.78 L3MBTL1 (0.62) L3MBTL1GLAITGB3ITGA2BSMN1; SMN2
SCHEMBL4328969 0.76 GRM2 (0.36) GRM2KDM4EHDAC2HDAC6
Hydrochloric Acid SCHEMBL22581399 0.76 ALOX15 (0.43) GRM2SMN1; SMN2
SCHEMBL31270000 0.76 L3MBTL1 (0.66) L3MBTL1ITGB3ITGA2BKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP claimed
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP disclosed
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS QLi5 Therapeutics AG (DE) 2024-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS PSMB5, PSMA5, PSMB1 L3MBTL1 2388/4885GLA 1223/4885ITGB3 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.